---
title: "Renewed Pharma and VC Interest in Osteoporosis Treatments After FDA Shift"
id: "stat-news-1-stat-drugmakers-biotech-vcs-show-reinvigorated-interest-in-osteoporosis"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-stat-drugmakers-biotech-vcs-show-reinvigorated-interest-in-osteoporosis"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/09/23/biotech-vc-investors-new-opportunity-osteoporosis-treatments/?utm_campaign=rss"
published_at: "2026-09-23T08:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Renewed Pharma and VC Interest in Osteoporosis Treatments After FDA Shift
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-stat-drugmakers-biotech-vcs-show-reinvigorated-interest-in-osteoporosis
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/09/23/biotech-vc-investors-new-opportunity-osteoporosis-treatments/?utm_campaign=rss)
- **Published At:** 2026-09-23T08:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Drugmakers and venture capitalists are showing a **reinvigorated** interest in developing treatments for **osteoporosis**, driven by regulatory changes and frustration with current therapies. - Historically, major pharmaceutical firms including Eli Lilly, Merck, Novartis, and GSK developed osteoporosis drugs, but uptake has been limited because of cumbersome dosing requirements and safety concerns. - Many eligible patients currently do not take any available osteoporosis therapies, creating an unmet treatment gap that investors and startups see as an opportunity. - A recent regulatory change at the **FDA** has provided new incentives that have renewed industry focus; the source notes a “long-awaited regulatory change” but does not detail the specific policy or timing. - Eli Lilly is specifically reported to be recruiting scientists to work on osteoporosis therapies; other companies are said to be considering similar investments, according to Bloomberg reporting cited in the source. - Venture capital firms have taken notice and are prioritizing **bone health** and osteoporosis as an investment area, though the source does not list specific VC firms, funding rounds, or startup names. - The source is a STAT+ (subscriber) story; substantial portions of the full article were behind a paywall and not available in the provided source content. As a result, exact details about the FDA change, specific company programs, clinical programs, trial data, timelines, and investor commitments were not reported in the accessible text. - Reported trends point to a potential shift in research and development activity for brittle bone disease, but precise implications for clinical practice, market size, or expected product launches were not provided in the excerpt.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/09/23/biotech-vc-investors-new-opportunity-osteoporosis-treatments/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/09/23/biotech-vc-investors-new-opportunity-osteoporosis-treatments/?utm_campaign=rss) [Cancer](https://www.statnews.com/topic/cancer/) [FDA](https://www.statnews.com/topic/fda/) [research](https://www.statnews.com/topic/research/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Biotech](https://www.statnews.com/category/biotech/) # Drugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatments ## Shift by the FDA and frustration with existing therapies have created new opportunities * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/09/23/biotech-vc-investors-new-opportunity-osteoporosis-treatments/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/09/osteoporosis-645x645.jpg) Camille MacMillin/STAT ![](https://www.statnews.com/wp-content/uploads/2022/04/allison-d-avatar-round-80x80.png) By [Allison DeAngelis](https://www.statnews.com/staff/allison-deangelis/) Sept. 23, 2026 Biotech Startups and Venture Capital Reporter ![](https://www.statnews.com/wp-content/uploads/2022/04/allison-d-avatar-round-80x80.png) [Allison DeAngelis](https://www.statnews.com/staff/allison-deangelis/) 1. [](https://x.com/ADeAngelis_bio "X") allison.deangelis@statnews.com Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “[The Readout Loud](https://www.statnews.com/category/readout-loud/).” You can reach Allison on Signal at AllisonDeAngelis.01. Medicines for brittle bones and breakages are grabbing the attention of the pharma industry, which has been incentivized by a long-awaited regulatory change. Osteoporosis, a condition affecting older adults that causes bones to become thin and fragile, used to be a top priority for pharmaceutical companies. Eli Lilly, Merck, Novartis, and GSK each had their own treatment designed to stop bones from weakening. But the cumbersome requirements for taking the drugs, as well as a series of safety concerns, stifled their use. Many patients who are eligible for osteoporosis therapies don’t take any of the drugs available today. Advertisement Several companies hope to fill that void. Eli Lilly is [recruiting scientists to work on osteoporosis therapies](https://www.bloomberg.com/news/articles/2026-09-10/lilly-s-glp-1-windfall-to-fund-investments-in-women-s-health), according to Bloomberg. Other pharmaceutical companies are rumored to be following suit. Venture capitalists, having taken notice, are now making bone health one of their priorities. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [chronic disease](https://www.statnews.com/topic/chronic-disease/), [drug development](https://www.statnews.com/topic/drug-development/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2022/04/allison-d-avatar-round-80x80.png) [Allison DeAngelis](https://www.statnews.com/staff/allison-deangelis/) 1. [](https://x.com/ADeAngelis_bio "X") 2. Biotech Startups and Venture Capital Reporter 1. [](https://x.com/ADeAngelis_bio "X") 2. Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “[The Readout Loud](https://www.statnews.com/category/readout-loud/).” You can reach Allison on Signal at AllisonDeAngelis.01. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/The-Readout-Logo-Black-640x99.png) ### Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2018/05/GettyImages-115791062-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [HHS unveils new initiatives to reduce animal testing in drug development](https://www.statnews.com/pharmalot/2026/09/22/hhs-initiatives-reduce-animal-testing-in-drug-development/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/09/alkermes-900-winter-st-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial](https://www.statnews.com/2026/09/21/alkermes-orexin-agonist-adhd-study/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/09/Dosing-Room-Layout-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Definium’s LSD therapy eased anxiety in second large trial](https://www.statnews.com/2026/09/14/definiums-lsd-therapy-eased-anxiety-large-trial-psychedelic/) 4. ![](https://www.statnews.com/wp-content/uploads/2025/04/AdobeStock_1068642359_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novo may be getting a better deal than expected with Medicare’s Bridge program](https://www.statnews.com/2026/09/22/biotech-news-novo-may-be-getting-a-better-deal-than-expected-with-medicare-bridge/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/02/AdobeStock_607424496-80x80.jpeg) [How AI is making me a better clinical psychologist](https://www.statnews.com/2026/02/11/ai-therapist-consultant-psychologist/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2025/12/AdobeStock_288008063-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Vera kidney drug Trutakna shows strong final results in Phase 3 trial](https://www.statnews.com/2026/09/15/vera-kidney-drug-trutakna-shows-strong-phase-3-results-igan/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/09/Eliza-treated-with-Gene-therapy-2016-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease](https://www.statnews.com/2026/09/17/sanfilippo-syndrome-treatment-ultragenyx-approval/) 3. ![](https://www.statnews.com/wp-content/uploads/2022/06/AdamsTake_Illustration_MollyFerguson_061322-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [A Sellas immunotherapy study, long delayed, will end in failure](https://www.statnews.com/2026/09/17/sellas-immunotherapy-study-acute-myeloid-leukemia/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/09/AP6802385202387510-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators](https://www.statnews.com/2026/09/21/grail-galleri-fda-advisory-committee-meeting-documents/) 5. ![](https://www.statnews.com/wp-content/uploads/2025/12/AdobeStock_1649079417-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [A biotech hedge fund births a new immunology company ](https://www.statnews.com/2026/09/17/biotech-hedge-fund-startup-north-immunology/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout September 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Novo may be getting a better deal than expected with Medicare’s Bridge program ](https://www.statnews.com/2026/09/22/biotech-news-novo-may-be-getting-a-better-deal-than-expected-with-medicare-bridge/) By [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Politics Politics September 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Ohio governor’s race is a battle over Covid, health costs, and trust in science ](https://www.statnews.com/2026/09/22/ohio-governor-election-health-care-policy-acton-ramaswamy/) By [Sarah Todd](https://www.statnews.com/staff/sarah-todd/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Health Health September 21, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators ](https://www.statnews.com/2026/09/21/grail-galleri-fda-advisory-committee-meeting-documents/) By [Matthew Herper](https://www.statnews.com/staff/matthew-herper/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout September 21, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Lilly’s breast cancer combo wins approval ](https://www.statnews.com/2026/09/21/biotech-news-lilly-breast-cancer-combo-wins-approval/) By STAT Staff ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech September 21, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial ](https://www.statnews.com/2026/09/21/alkermes-orexin-agonist-adhd-study/) By [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: A Sellas immunotherapy study, long delayed, will end in failure ](https://www.statnews.com/2026/09/17/sellas-immunotherapy-study-acute-myeloid-leukemia/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease ](https://www.statnews.com/2026/09/17/sanfilippo-syndrome-treatment-ultragenyx-approval/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) 3. ### ![](https://www.statnews.c
## Related Clinical Research

- [Sen. Warren demands access to Trump drug-pricing contracts, accuses RFK Jr. of concealing them](https://medichelpline.com/clinical-feed/stat-news-0-stat-sen-warren-demands-to-see-trump-drug-pricing-pharma-contracts-accuses-rfk.md)
- [AstraZeneca breast cancer pill fails pivotal trial; Scholar Rock wins FDA approval for SMA muscle-](https://medichelpline.com/clinical-feed/stat-news-1-stat-pharmalittle-we-re-reading-about-another-astrazeneca-trial-failure-a-novo.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Keto Diet Shows Superior Metabolic Benefits Over Mediterranean and Low-Fat Diets](https://medichelpline.com/clinical-feed/medical-news-today-1-keto-diet-may-have-metabolic-advantages-over-mediterranean-low-fat-diets.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.